CLINICAL CO-DEVELOPMENT AGREEMENTDevelopment Agreement • March 22nd, 2023 • Phio Pharmaceuticals Corp. • Pharmaceutical preparations • Delaware
This Clinical Co-Development Agreement (“Agreement”), entered into as of February 26, 2021 (the “Effective Date”), is by and between Phio Pharmaceuticals Corp., a Delaware corporation, having its principal offices at 257 Simarano Dr., Marlborough, MA 01752 (“Phio”), and AgonOx, Inc., an Oregon corporation, having its principal offices at 4805 NE Glisan St., Portland, OR 97213 (“AgonOx”). Phio and AgonOx may be referred to herein each individually as a “Party” and collectively as the “Parties.”
SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMSSeparation Agreement • March 22nd, 2023 • Phio Pharmaceuticals Corp. • Pharmaceutical preparations • Massachusetts
This SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (this “Agreement”) is entered into by and between Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”) and Gerrit D. Dispersyn, Dr. Med. Sc. (the “Executive”) (each of the foregoing individually a “Party” and collectively the “Parties”).
